Viramune 400 mg Prolonged-Release Tablets - Summary of

Go to content

Main menu:

Viramune XR (nevirapine) Drug / Medicine Information

Viramune 400 mg Prolonged-Release Tablets - Summary of , Viramune XR (nevirapine) Drug / Medicine Information, Viramune (Nevirapine Tablets) Information -, Viramune XR Prices, Coupons & Patient Assistance Programs , Viramune and Viramune XR HIV Medication - POZ, VIRAMUNE Tablets XR Extended-Release Tablets VIRAMUNE Oral , Viramune XR -, Reference ID: 3214495 - Food and Drug Administration.
Renal impairment: The single-dose pharmacokinetics of nevirapine immediate-release has been compared in 23 patients with either mild (50 ≤ CLcr < 80 ml/min), moderate (30 ≤ CLcr < 50 ml/min) or severe renal dysfunction (CLcr < 30 ml/min), renal impairment or end-stage renal disease (ESRD) requiring dialysis, and 8 patients with normal renal function (CLcr > 80 ml/min). Renal impairment (mild, moderate and severe) resulted in no significant change in the pharmacokinetics of nevirapine. However, patients with ESRD requiring dialysis exhibited a 43.5 % reduction in nevirapine AUC over a one-week exposure period. There was also accumulation of nevirapine hydroxy-metabolites in plasma. The results suggest that supplementing nevirapine therapy for adults with an additional 200 mg immediate-release tablet following each dialysis treatment would help offset the effects of dialysis on nevirapine clearance. Otherwise patients with CLcr ≥ 20 ml/min do not require an adjustment in nevirapine dosing. In paediatric patients with renal dysfunction who are undergoing dialysis it is recommended following each dialysis treatment patients receive an additional dose of Viramune oral suspension or immediate-release tablets representing 50 % of the recommended daily dose of Viramune oral suspension or immediate-release tablets, which would help offset the effects of dialysis on nevirapine clearance. Viramune prolonged-release tablets have not been studied in patients with renal dysfunction and Viramune immediate-release should be used.. Viramune is indicated in combination with other anti-retroviral medicinal products for the treatment of HIV-1 infected adults, adolescents, and children three years and above and able to swallow tablets (see section 4.2)..
Viramune XR extended-release tablets 400 mg are yellow, oval, biconvex tablets. The tablets are embossed with product identification "V04" on one side and the BI tower logo on the other side.. Warning Very bad and sometimes deadly liver problems have happened with Viramune (nevirapine tablets). The chance is highest within the first 18 weeks of taking this drug, but can happen at any time.. Viramune XR Prices, Coupons and Patient Assistance Programs. Viramune XR (nevirapine) is a member of the NNRTIs drug class and is commonly used for HIV Infection. Viramune XR Prices . This Viramune XR price guide is based on using the discount card which is accepted at most U.S. pharmacies. The cost for Viramune XR oral tablet, extended release 400 mg is around $886 for a supply of . Viramune is available as an immediate-release (IR) tablets, which is taken twice a day, and as an extended-release tablet (XR), which is taken once a day. Viramune must be used in combination with other HIV drugs.. Viramune is available as release immediateViramune - tablets, extendedrelease - Viramune XR tablets or as a suspension for oral administration. Each Viramune immediate-release tablet contains 200 mg of nevirapine and the inactive. Viramune XR 400 mg extended-release tablet the next morning and do not take any more of the Viramune immediate-release tablets or oral suspension. How to take it Swallow the tablets whole with a full glass of water. The tablets should not be broken, crushed or chewed. The tablets can be taken with or without food. When to take it Take your medicine at about the same time each day. Taking it at .
Copyright 2019. All rights reserved.
Back to content | Back to main menu